Amneal Pharmaceuticals Donates $2 Million To Support Parkinson’s Patients And Expand Access To Essential Treatments

Amneal Pharmaceuticals, Inc. has announced $2 million in donations to multiple patient assistance foundations to support individuals living with Parkinson’s disease. The initiative, aligned with Parkinson’s Awareness Month, reflects the company’s commitment to improving access to treatment and strengthening support systems for patients and caregivers.

Parkinson’s disease continues to pose a growing global health challenge, with millions affected worldwide and new diagnoses occurring frequently. As the condition progresses, patients often face increasing physical limitations, emotional strain, and financial burdens. Amneal’s contributions aim to ease these challenges by helping eligible patients manage out-of-pocket expenses, such as copayments, coinsurance, and deductibles, for FDA-approved therapies.

“Parkinson’s disease has a profound and far-reaching impact on patients, families, and care partners,” said Chirag Patel and Chintu Patel, Co-Chief Executive Officers of Amneal. “At Amneal, expanding access to essential medicines is core to our purpose. Over the past two years, we have donated $3.5 million to support patients living with Parkinson’s disease, and we remain committed to working alongside the community to help improve access to treatment, education, and support for those navigating this condition.”

Beyond financial support, the company is actively working to enhance the quality of life for patients and their caregivers through education and advocacy. Amneal engages with the community by sharing patient stories, participating in awareness initiatives, and offering educational resources, including materials tailored for Spanish-speaking populations.

Through these efforts, Amneal is encouraging broader participation in Parkinson’s Awareness Month, urging individuals and organizations to support advocacy initiatives, raise awareness, and improve access to essential healthcare resources for the Parkinson’s community.